Entering regenerative medicine through human-derived cosmetic ingredients and automated cell-culture equipment
First written in FY2023-Q1. 10 of 13 entries say "Advanced", first in FY2023-Q3. Latest entry: 2026-08-13.
1 other company's latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「The newly built cell-culture processing facility in Amagasaki, Hyogo Prefecture, obtained a license to manufacture specified cell-processed products on 8 April 2025 and commenced full-scale operations in preparation for future demand growth.」
The cell-culture processing facility in Amagasaki, Hyogo Prefecture, obtained its license on 8 April 2025 and commenced full-scale operations. The scheduled completion of the cell-culture robot has also been changed from August 2025 to March 2026. - FY2025-H1SoftenedAnnual report
「The total planned investment amount has changed from ¥190.000 million to ¥183.459 million. The amount already paid against the planned investment has changed from ¥26.937 million to ¥100.942 million. The scheduled completion date has changed from July 2024 to November 2024.」
For the Hyogo CPF, the amount already paid increased, while the total planned investment was changed to ¥183.459 million and the scheduled completion was changed from July to November 2024. Although revenue from the regenerative medicine-related business increased, the facility development schedule has been pushed back. - FY2024AdvancedAnnual report
「In the regenerative medicine-related business, we made active investments during the current fiscal year, including developing an automated cell-culture robot and constructing a cell-culture processing facility, while establishing the business foundation. As a result of commencing full-scale operations, revenue and operating income substantially exceeded the initial forecasts. Revenue was ¥409.430 million, up ¥363.069 million from the previous consolidated fiscal year, and operating income was ¥35.758 million, up ¥26.986 million.」
Development of the automated cell-culture robot and construction of the cell-culture processing facility progressed, and the business recorded revenue of ¥409.430 million and operating income of ¥35.758 million after commencing full-scale operations. Operating income increased from ¥8.771 million in the previous fiscal year. - FY2024-Q3AdvancedAnnual report
「We also made active investments, including developing an automated cell-culture robot and constructing a cell-culture processing facility. Strong contract manufacturing of human-derived ingredients and cosmetics OEM products resulted in revenue of ¥261.025 million and operating income of ¥10.404 million.」
In the regenerative medicine-related business centered on RMDC, development of an automated cell-culture robot and investment in construction of a cell-culture processing facility progressed. The Hyogo CPF was planned at a total cost of ¥190.000 million, with work scheduled to begin in January 2024 and be completed in July of that year. The business recorded revenue of ¥261.025 million and operating income of ¥10.404 million, returning to profitability. - FY2024-Q2AdvancedAnnual report
「Strong contract manufacturing of ingredients and OEM products using human-derived materials resulted in revenue of ¥168.415 million and operating income of ¥1.300 million.」
Following the consolidation of RMDC as a subsidiary, contract manufacturing of human-derived ingredients and OEM products performed well, and the regenerative medicine-related business recorded revenue of ¥168.415 million and operating income of ¥1.300 million, returning to profitability. - FY2024-Q1AdvancedAnnual report
「Contract manufacturing of OEM products using human-derived stem-cell culture medium was strong, but amortization of goodwill resulted in revenue of ¥92.924 million and an operating loss of ¥99,000.」
Following the acquisition of RMDC as a wholly owned subsidiary, contract manufacturing of OEM products using human-derived stem-cell culture medium performed well, and the regenerative medicine-related business recorded revenue of ¥92.924 million. Investment in the development of an automated cell-culture robot also continued. - FY2023AdvancedAnnual report
「In the regenerative medicine-related business, commercialization progressed rapidly after 株式会社ＲＭＤＣ, which was already engaged in the regenerative medicine-related business, became a wholly owned subsidiary.」
Following the acquisition of 株式会社RMDC as a wholly owned subsidiary, commercialization of the regenerative medicine-related business progressed. The sustainable and regenerative medicine-related business, including this segment, recorded revenue of ¥57.145 million and an operating loss of ¥52.940 million. - FY2023-Q3AdvancedAnnual report
「To further expand the regenerative medicine-related business and promote sales of human-derived cosmetic ingredients in that business, our group made 株式会社ＲＭＤＣ a wholly owned subsidiary in January 2023. Going forward, we will sell human-derived cosmetic ingredients to cosmetics manufacturers, ingredient manufacturers, and other customers. We will also step up investment in cell-culture facilities and automated cell-culture robots to develop human-derived cosmetic ingredients with high functionality that are recognized and traded in the cosmetics industry as high-priced ingredients. Development of the automated cell-culture robot is under way, with completion targeted for fiscal 2023.」
To promote sales of human-derived cosmetic ingredients, the company made 株式会社ＲＭＤＣ a wholly owned subsidiary. In addition to ingredient sales, it is investing in cell-culture facilities and an automated cell-culture robot, with completion of the robot targeted for fiscal 2023. - FY2023-Q2RestatedAnnual report
「We aim to complete the automated cell-culture equipment during 2023 and will sell it to medical institutions and other organizations in Japan and overseas.」
The plan to complete the automated cell-culture equipment during 2023 and sell it to medical institutions and other organizations in Japan and overseas has been reiterated. - FY2023-Q1First statedAnnual report
「We aim to complete the automated cell-culture equipment during 2023 and will sell it to medical institutions and other organizations in Japan and overseas.」
A new plan has been disclosed to complete the automated cell-culture equipment during 2023 and sell it to medical institutions and other organizations in Japan and overseas, in addition to selling human-derived cosmetic ingredients and investing in cell-culture facilities.